Details Basic Details Approval Date Wednesday, February 15, 2017 Health Outcome(s) malignancy, adverse pregnancy and fetal outcomes, outpatient neutropenia, opportunistic infections, fatal major adverse cardiac events, suicidal ideation and behavior, hospitalized neutropenia, myocardial infarction and stroke, serious infection Regulatory Link(s) (2) ARIA Memo FDA Approval Package Link(s) Sentinel Drug Study: Siliq (Brodalumab) & Hospitalized Neutropenia, Myocardial Infarction and Stroke, and Serious Infection